P963: EVOLUTION OF TREATMENT PATTERNS AND OVERALL SURVIVAL IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA RECEIVING A SECOND LINE OF THERAPY BETWEEN 2012 AND 2020: ANALYSIS OF THE PREAMBLE COHORT

• D. Kuter,
• H. Goldschmidt,
• D. Cella,
• M. T. Petrucci,
• P. Moreau,
• B. Durie,
• A. Juarez-Garcia,
• L. Trong,
• J. Gu,
• G. Hernandez Rivera,
• S. Dhanasiri,
• T. Marshall,
• J. Wang,
• L. Lacoin,
• K. Ramasamy,
• R. Vij

Affiliations

D. Kuter

1 Hematology Division, Massachusetts General Hospital, Boston, MA, United States of America

H. Goldschmidt

2 University Hospital Heidelberg, Internal Medicine V and National Center for Tumor Diseases (NCT), Heidelberg, Germany

D. Cella

3 Department of Medical Social Sciences and Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL, United States of America

M. T. Petrucci

4 Department of Cellular Biotechnologies and Hematology, Sapienza University of Rome, Rome, Italy

P. Moreau

5 Service d’hématologie clinique, CHU Hôtel Dieu, Nantes, France

B. Durie

6 Cedars Sinai Cancer Center, Los Angeles, CA

A. Juarez-Garcia

7 Bristol Myers Squibb, Princeton, NJ, United States of America

L. Trong

7 Bristol Myers Squibb, Princeton, NJ, United States of America

J. Gu

7 Bristol Myers Squibb, Princeton, NJ, United States of America

G. Hernandez Rivera

8 Bristol-Myers Squibb, Boudry, Switzerland

S. Dhanasiri

8 Bristol-Myers Squibb, Boudry, Switzerland

T. Marshall

7 Bristol Myers Squibb, Princeton, NJ, United States of America

J. Wang

7 Bristol Myers Squibb, Princeton, NJ, United States of America

L. Lacoin

9 Epi-Fit, Bordeaux, France

K. Ramasamy

10 Department of Haematology, Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom

R. Vij

11 Siteman Cancer Center, Washington University in St. Louis, St. Louis, MO, United States of America